文献速递特殊人群用药

生理药代动力学模型表征年龄与肥胖对儿童左乙拉西坦处置的影响

Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
PubMed 文献 · Clin Pharmacokinet · 2024-05-30

本研究利用两项前瞻性标准诊疗儿童试验(n=88,年龄1月龄至19岁,含64%肥胖者)的PK数据,扩展已发布的儿童左乙拉西坦PBPK模型至2岁以下及2岁以上肥胖儿童。82.4%数据落在模型预测90%区间内,平均fold error在二倍以内;肥胖儿童体重归一化清除率(0.053 L/h/kg)低于非肥胖儿童(0.063 L/h/kg)。模拟显示现行FDA儿童剂量方案可为目标人群产生所需暴露,但4岁至16岁以下肥胖儿童需调整剂量。

要点

  • 肥胖儿童左乙拉西坦体重归一化清除率低于非肥胖儿童。
  • PBPK模型预测与观察数据吻合良好,82.4%数据落在90%预测区间内。
  • 4岁至16岁以下肥胖儿童需按现行FDA标签调整剂量以保证暴露。

核心结论

  • PBPK模拟显示现行FDA儿童左乙拉西坦剂量方案可为目标人群产生所需暴露,但4岁至16岁以下肥胖儿童需调整剂量。

研究设计与样本

  • 研究利用两项前瞻性标准诊疗儿童试验的PK数据(n=88,年龄1月龄至19岁,含64%肥胖者),使用PK-Sim®软件扩展已发表的2岁及以上儿童左乙拉西坦PBPK模型至2岁以下及2岁以上肥胖儿童,并用前瞻性数据及文献新生儿和2岁以下儿童数据评估模型。

主要发现

  • 总体82.4%的数据落在模型预测浓度的90%区间内,平均fold error在公认标准的二倍以内。
  • PBPK建模显示肥胖儿童平均体重归一化清除率为0.053 L/h/kg,低于非肥胖儿童的0.063 L/h/kg。
  • 成熟度效应被良好表征,模拟的体重归一化清除率与文献报道的新生儿和2岁以下儿童相当。

关键数值与推荐

  • 肥胖儿童平均体重归一化清除率为0.053 L/h/kg,非肥胖儿童为0.063 L/h/kg。
  • 82.4%的数据落在模型预测浓度的90%区间内,平均fold error在二倍以内。

临床怎么用

  • 对于4岁至16岁以下肥胖儿童,可依据PBPK模拟结果调整左乙拉西坦剂量以达所需暴露。
  • 现行FDA标签儿童剂量方案可用于目标人群,但肥胖儿童需注意剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Levetiracetam is an antiseizure medication used for several seizure types in adults and children aged 1 month and older; however, due to a lack of data, pharmacokinetic (PK) variability of levetiracetam is not adequately characterized in certain populations, particularly neonates, children younger than 2 years of age, and children older than 2 years of age with obesity. OBJECTIVE: This study aimed to address the gap by leveraging PK data from two prospective standard-of-care pediatric trials (n = 88) covering an age range from 1 month to 19 years, including those with obesity (64%), and applying a physiologically based PK (PBPK) modeling framework. METHODS: A published PBPK model of levetiracetam for children aged 2 years and older was extended to pediatric patients younger than 2 years of age and patients older than 2 years of age with obesity by accounting for the obesity and age-related changes in PK using PK-Sim® software. The prospective pediatric data, along with the literature data for neonates and children younger than 2 years of age, were used to evaluate the extended PBPK models. RESULTS: Overall, 82.4% of data fell within the 90% interval of model-predicted concentrations, with an average fold error within twofold of the accepted criteria. PBPK modeling revealed that children with obesity had lower weight-normalized clearances (0.053 L/h/kg) on average than children without obesity (0.063 L/h/kg). The effect of maturation was well-characterized, resulting in comparable PBPK-simulated, weight-normalized clearances for neonates and children younger than 2 years of age reported from the literature. CONCLUSIONS: PBPK modeling simulations revealed that the current US FDA-labeled pediatric dosing regimen listed in the prescribing information can produce the required exposure of levetiracetam in these target populations with dose adjustments for children with obesity aged 4 years to younger than 16 years.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Maglalang PD, Sinha J, Zimmerman K, et al. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. Clin Pharmacokinet. 2024. PMID: 38814425. doi:10.1007/s40262-024-01367-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。